Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 20-F, Date: 2017-11-22, XBRL Interactive Financials
Original SEC Filing: Click here

---

Webplus: SVA/20171122/20-F/1/000.htm SEC Original: tv479639_20f.htm

---

---

Webplus: SVA/20171122/20-F/2_EX-8.1/000.htm SEC Original: tv479639_ex8-1.htm
List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Sinovac Biotech Co., Ltd., a PRC company 3. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 4. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company 5. Sinovac Biomed Co., Ltd. (formerly known as Sinovac Zhong

---

---

Webplus: SVA/20171122/20-F/3_EX-12.1/000.htm SEC Original: tv479639_ex12-1.htm
CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of

---

---

Webplus: SVA/20171122/20-F/4_EX-12.2/000.htm SEC Original: tv479639_ex12-2.htm
CERTIFICATION BY THE CHIEF FINANCIAL OFFICER I, Nan Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of

---

---

Webplus: SVA/20171122/20-F/5_EX-13.1/000.htm SEC Original: tv479639_ex13-1.htm
CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Weidong Yin Chairman and Chief Executive Officer

---

---

Webplus: SVA/20171122/20-F/6_EX-13.2/000.htm SEC Original: tv479639_ex13-2.htm
CERTIFICATION BY THE CHIEF FINANCIAL OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Nan Wang Chief Financial Officer

---

---

Webplus: SVA/20171122/20-F/7_EX-15.1/000.htm SEC Original: tv479639_ex15-1.htm
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: i) Registration Statement (Form S-8 No. 333-161827) pertaining to Sinovac Biotech Ltd.’s 2003 Stock Option Plan; and ii) Registration Statement (Form S-8 No. 333-190980) pertaining to Sinovac Biotech Ltd.’s 2012 Share Incentive Plan; of our reports dated November 22, 2017, with

---

Company Info:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 20-F, Date: 2017-11-22, XBRL Interactive FinancialsCIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
39 SHANGDI XI ROAD, HAIDIAN DISTRICT
BEIJING 100085